Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

HUTCHMED (China) Limited (H7T1.F)

Compare
11.80
+0.10
+(0.85%)
As of 8:03:46 AM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for H7T1.F

Recent News: H7T1.F

View More
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
GlobeNewswire 27 days ago
HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. 27 days ago
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
GlobeNewswire 28 days ago
HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...

HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...
GuruFocus.com 28 days ago
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
GlobeNewswire 28 days ago
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
GlobeNewswire 28 days ago
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
GlobeNewswire 29 days ago
HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years

HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years
Simply Wall St. last month
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
GlobeNewswire last month
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
GlobeNewswire last month
HUTCHMED to Announce 2024 Final Results

HUTCHMED to Announce 2024 Final Results
GlobeNewswire last month
View More